Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.
about
Optimizing the management of advanced non-small-cell lung cancer: a personal viewClinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic reviewResults of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancerThe Lake Wobegon effect: are all cancer patients above average?Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study GroupGemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC)Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumabCisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing resultsAnticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database.Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel.A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer.Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated.A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma.Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer.Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430.A 21-day schedule of gemcitabine and cisplatin administration in the treatment of advanced non-small cell lung carcinoma: a phase II study[A randomized clinical trial on the clinical efficacy and toxicities of single-agent paclitaxel liposome versus paclitaxel liposome plus oxaliplatin as first-line chemotherapy for advanced non-small cell lung cancer in elderly patients].Triplet chemotherapy combination with cisplatin, gemcitabine and docetaxel in patients with chemotherapy-naive advanced non-small cell lung cancer.nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer.IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions.Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer - a retrospective analysis: JMTO LC03-02Challenges to National Cancer Institute-Supported Cooperative Group Clinical Trial Participation: An ASCO Survey of Cooperative Group Sites.Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in womNovel combination chemotherapy in the treatment of non-small cell lung cancer.Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer.Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies.Increased NQO1 but not c-MET and survivin expression in non-small cell lung carcinoma with KRAS mutationsThe impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trialsDynamics of tumor hypoxia in response to patupilone and ionizing radiationPhase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancerDoes histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594Effect of computer support on younger women with breast cancerThe case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).Lung cancer--where are we today? Current advances in staging and nonsurgical treatment.Triplet chemotherapy with vinorelbine, gemcitabine, and cisplatin for advanced non-small cell lung cancer: a phase II studyAdvanced NSCLC: from cytotoxic systemic chemotherapy to molecularly targeted therapy.Lung cancer. 4: chemotherapy for non-small cell lung cancer: the end of the beginning.Gefitinib (Iressa): a novel treatment for non-small cell lung cancer.Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study.
P2860
Q24656144-5E269C1E-E939-4AE0-B526-E04489268F80Q24678961-173C5689-04B8-4B9E-875A-02AE71D87224Q24799908-EE772D8D-F061-472F-B03D-1F7ED3116D87Q28303620-2E249828-40DD-4BCF-9E7C-D45632D7AE49Q28343462-C2104959-A5E4-4E6A-887F-6A012080560FQ28364865-B19F1521-15AE-4390-9CAA-2EA2BC1D1ADEQ28388270-43C73186-DF21-4BDE-93FD-29CCFA565B79Q30784508-3BD11E00-B3B0-45E4-8E29-F5A35C4F2922Q30886032-1C08C288-5170-4982-947B-33910EF766BEQ33248481-1F3400B1-518C-4FC8-BA84-E9D9F8BDC4E6Q33338040-3CFAEDD1-F24C-4DAA-B2ED-90AEE3C48AFDQ33341156-48D03CA4-94CD-4CEE-B549-3C4AFB4B5375Q33341208-EBD2CEEE-50B1-4A53-891D-487609265E40Q33344553-C51F16CC-ECBB-4DF7-B4A5-93CA60B78EC8Q33366782-13B41E08-C9F1-4059-BAB9-C1180CFD411FQ33381874-F8774316-9C4D-4FB4-B7CD-4A752263F2C5Q33389166-24FC612B-D01A-49B8-99C4-574A6215E8B4Q33399713-59E37FDF-BD69-4618-AC3F-EEA7C736CE3EQ33408330-4289FD31-4FF0-4ADF-A3E7-A16F6E76B163Q33412928-B8713FD6-A0DE-4A5A-AEE3-C4CFCC8DD0AFQ33479161-43E775DD-6526-42CE-B39C-A77B40E0AED6Q33490820-57A54217-0EB6-491C-833E-0ECE9B9B7ED1Q33846151-9C952323-166D-417D-8BCE-2807F71A720BQ33904763-DB432AFE-9C9B-47B2-8ED4-A18F656D28FAQ34181910-98753BBF-096A-4418-9462-838782E0BACBQ34203414-CEAEE9FB-C945-4C01-8AA6-138B17314BA6Q34325219-94B5729E-3060-408D-A765-46605296DB0EQ34348237-C5F65029-1C6B-4A90-ACF5-D00043EF6109Q34352408-466010E5-C9F0-4E0E-B829-F2396AEB2372Q34516719-E69C5C2E-FFB3-40CA-B901-0F576D19A02BQ34594899-B0905C76-0F00-488B-B15F-632242990089Q34688296-7CA1DB7B-9C68-44B2-9131-179D118AC935Q34743981-1B893F96-659A-4253-83DE-B41AF6230A20Q34791240-AE80DCCD-C509-4554-9874-15593D196654Q34982142-20A77F9D-8542-4145-9831-EC08BF9649A2Q35010260-C78B3444-7B8C-409A-B305-2ECCD63BB0C5Q35089127-203F1532-D8F6-4CF1-8A28-27626CA46378Q35096015-325CB9F8-B9BD-4F24-A16C-4226FA158421Q35641188-744DA1F7-3650-43B5-AA9E-75CF09EDF4EBQ35808418-5ADC1ACB-937E-401A-B725-1F1BDE856965
P2860
Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Comparison of survival and qua ...... perative Oncology Group trial.
@en
Comparison of survival and qua ...... perative Oncology Group trial.
@nl
type
label
Comparison of survival and qua ...... perative Oncology Group trial.
@en
Comparison of survival and qua ...... perative Oncology Group trial.
@nl
prefLabel
Comparison of survival and qua ...... perative Oncology Group trial.
@en
Comparison of survival and qua ...... perative Oncology Group trial.
@nl
P2093
P1476
Comparison of survival and qua ...... perative Oncology Group trial.
@en
P2093
D Fairclough
E Rowinsky
M Jiroutek
P304
P356
10.1200/JCO.2000.18.3.623
P407
P577
2000-02-01T00:00:00Z